Home  |  Contact

UniProtKB/Swiss-Prot P05155: Variant p.Arg466Cys

Plasma protease C1 inhibitor
Variant information

Variant position:  466
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Cysteine (C) at position 466 (R466C, p.Arg466Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HAE; phenotype consistent with hereditary angioedema type 2.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  466
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  500
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.




Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 23 – 500 Plasma protease C1 inhibitor
Site 465 – 466 Reactive bond for chymotrypsin
Site 466 – 467 Reactive bond

Literature citations

Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema.
Kalmar L.; Bors A.; Farkas H.; Vas S.; Fandl B.; Varga L.; Fuest G.; Tordai A.;
Hum. Mutat. 22:498-498(2003)
Cited for: VARIANTS HAE TYR-130; PRO-394; VAL-408; CYS-466; GLU-473; GLU-493 AND ARG-498;

Mutational spectrum and geno-phenotype correlation in Chinese families with Hereditary Angioedema.
Xu Y.Y.; Zhi Y.X.; Yin J.; Wang L.L.; Wen L.P.; Gu J.Q.; Guan K.; Craig T.; Zhang H.Y.;
Allergy 67:1430-1436(2012)
Cited for: VARIANTS HAE ALA-118; CYS-154; PHE-170; ARG-184; PRO-230; LYS-232; ASN-272 DEL; ARG-299; GLN-430; THR-441; PRO-447; SER-466; CYS-466; LEU-466; GLY-473 AND GLY-497; VARIANTS ALA-56 AND MET-480;

Mutational spectrum of the c1 inhibitor gene in a cohort of Italian patients with hereditary angioedema: description of nine novel mutations.
Bafunno V.; Bova M.; Loffredo S.; Divella C.; Petraroli A.; Marone G.; Montinaro V.; Margaglione M.; Triggiani M.;
Ann. Hum. Genet. 78:73-82(2014)
Cited for: VARIANTS HAE ARG-11; ARG-265; VAL-274; THR-458; CYS-466; HIS-466; ARG-493 AND GLU-493;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.